Parkinson's Disease/Movement Disorders News

Topline data from a phase 2 clinical trial of an investigational gene therapy for Parkinson’s disease showed that a higher dose of the medication significantly improved disease-specific and quality of life measures by week 26.

The FDA has approved Vyalev, a continuous, subcutaneous 24-hour infusion, to address motor fluctuations in adults with advanced Parkinson's disease, according to the manufacturer.

The NIH has awarded a $3.3 million grant to advance a novel, oral silent allosteric modulator intended to treat Alzheimer’s and Parkinson’s diseases, according to the manufacturer.

ORLANDO, Fla. — A pilot study of direct spinal cord stimulation showed promise for improving motor function in a small cohort of individuals with gait freezing in Parkinson’s disease, according to a presenter.

ORLANDO, Fla. — A “hub-and-spoke” model for Parkinson’s disease care featuring multiple regional centers that offered telehealth was effective at closing access gaps for individuals in Arkansas, according to a poster.

ORLANDO, Fla. — Glymphatic function, as measured by an index of system clearance, is associated with rates of cognitive and motor decline as well as disability worsening in Parkinson’s disease, according to a poster.

The presence of mucosal damage on upper gastrointestinal endoscopy was associated with a 76% greater risk for developing Parkinson’s disease, underscoring the need for “increased vigilance” among these patients, according to a cohort study.

Individuals who engaged in some form of exercise or physical activity on a regular or semi-regular basis demonstrated better brain health compared with inactive individuals, according to research from Nature Aging.

Deep brain stimulation (DBS) therapy has been a safe and effective treatment option for Parkinson’s disease for more than 30 years, but another surgical option for the therapy has emerged.